[go: up one dir, main page]

MX336980B - Combinacion y composicion para el tratamiento de obesidad. - Google Patents

Combinacion y composicion para el tratamiento de obesidad.

Info

Publication number
MX336980B
MX336980B MX2010014484A MX2010014484A MX336980B MX 336980 B MX336980 B MX 336980B MX 2010014484 A MX2010014484 A MX 2010014484A MX 2010014484 A MX2010014484 A MX 2010014484A MX 336980 B MX336980 B MX 336980B
Authority
MX
Mexico
Prior art keywords
combination
composition
treating obesity
present
obesity
Prior art date
Application number
MX2010014484A
Other languages
English (en)
Other versions
MX2010014484A (es
Inventor
Salgado López Raúl García
Hernández Gustavo Barranco
Peláez Juan Pablo Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Priority to MX2010014484A priority Critical patent/MX336980B/es
Priority to PE2013001445A priority patent/PE20140697A1/es
Priority to PCT/IB2011/055723 priority patent/WO2012085785A1/es
Priority to US13/996,410 priority patent/US9433602B2/en
Priority to ES201390069A priority patent/ES2422877B1/es
Priority to GB1312583.6A priority patent/GB2500357B/en
Priority to CA2822213A priority patent/CA2822213C/en
Priority to RU2013127794A priority patent/RU2608928C2/ru
Priority to BR112013015489-6A priority patent/BR112013015489A2/pt
Priority to ARP110104818A priority patent/AR084435A1/es
Publication of MX2010014484A publication Critical patent/MX2010014484A/es
Priority to CL2013001731A priority patent/CL2013001731A1/es
Priority to CR20130298A priority patent/CR20130298A/es
Priority to DO2013000144A priority patent/DOP2013000144A/es
Priority to GT201300169A priority patent/GT201300169A/es
Priority to CO13153451A priority patent/CO6751242A2/es
Publication of MX336980B publication Critical patent/MX336980B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención tiene su aplicación en el campo farmacéutico, especialmente en el de combinación y composiciones farmacéuticas que comprenden un inhibidor de la lipasa y una fitoalexina y vehículos o excipientes farmacéuticamente aceptables; la presente invención también se relaciona con el proceso de fabricación de composiciones que contienen la combinación y el uso de dicha composición en el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados.
MX2010014484A 2010-12-21 2010-12-21 Combinacion y composicion para el tratamiento de obesidad. MX336980B (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MX2010014484A MX336980B (es) 2010-12-21 2010-12-21 Combinacion y composicion para el tratamiento de obesidad.
PCT/IB2011/055723 WO2012085785A1 (es) 2010-12-21 2011-12-16 Combinación y composición para el tratamiento de obesidad
CA2822213A CA2822213C (en) 2010-12-21 2011-12-16 Combination and composition for treating obesity
BR112013015489-6A BR112013015489A2 (pt) 2010-12-21 2011-12-16 combinação e composição para o tratamento de obesidade
US13/996,410 US9433602B2 (en) 2010-12-21 2011-12-16 Combination and composition for treating obesity
ES201390069A ES2422877B1 (es) 2010-12-21 2011-12-16 Combinación y composición para el tratamiento de obesidad
GB1312583.6A GB2500357B (en) 2010-12-21 2011-12-16 Combination and composition for treating obesity
PE2013001445A PE20140697A1 (es) 2010-12-21 2011-12-16 Combinacion y composicion para el tratamiento de obsidad
RU2013127794A RU2608928C2 (ru) 2010-12-21 2011-12-16 Фармацевтическая комбинация и композиция для лечения ожирения и ее применение
ARP110104818A AR084435A1 (es) 2010-12-21 2011-12-20 Combinacion y composicion para el tratamiento de obesidad
CL2013001731A CL2013001731A1 (es) 2010-12-21 2013-06-14 Una combinacion farmaceutica sinergica que comprende orlistat o sus sales y resveratrol o sus sales; composicion farmaceutica que comprende a dicha combinacion sinergica; su proceso de preparacion; y su uso para el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados.
CR20130298A CR20130298A (es) 2010-12-21 2013-06-19 Combinación y composición para el tratamiento de la obesidad
DO2013000144A DOP2013000144A (es) 2010-12-21 2013-06-20 Combinacion y composicion para el tratamiento de obesidad
GT201300169A GT201300169A (es) 2010-12-21 2013-06-21 Combinacion y composicion para el tratamiento de obesidad
CO13153451A CO6751242A2 (es) 2010-12-21 2013-06-28 Combinación y composición para el tratamiento de obesidad

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014484A MX336980B (es) 2010-12-21 2010-12-21 Combinacion y composicion para el tratamiento de obesidad.

Publications (2)

Publication Number Publication Date
MX2010014484A MX2010014484A (es) 2012-06-21
MX336980B true MX336980B (es) 2016-02-09

Family

ID=46313244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014484A MX336980B (es) 2010-12-21 2010-12-21 Combinacion y composicion para el tratamiento de obesidad.

Country Status (15)

Country Link
US (1) US9433602B2 (es)
AR (1) AR084435A1 (es)
BR (1) BR112013015489A2 (es)
CA (1) CA2822213C (es)
CL (1) CL2013001731A1 (es)
CO (1) CO6751242A2 (es)
CR (1) CR20130298A (es)
DO (1) DOP2013000144A (es)
ES (1) ES2422877B1 (es)
GB (1) GB2500357B (es)
GT (1) GT201300169A (es)
MX (1) MX336980B (es)
PE (1) PE20140697A1 (es)
RU (1) RU2608928C2 (es)
WO (1) WO2012085785A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2025162329A1 (en) * 2024-01-30 2025-08-07 Caliway Biopharmaceuticals Co., Ltd. Oxyresveratrol and derivatives thereof for use in lipolysis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1838273A4 (en) * 2005-01-10 2013-02-20 Elc Man Llc DISCONTINUOUS SURFACE COATING FOR PARTICLES
CA2613141A1 (en) 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7771632B2 (en) * 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
US20100196464A1 (en) * 2007-09-17 2010-08-05 Dr. Reddy's Laboratories Limited Orlistat pharmaceutical formulations
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity

Also Published As

Publication number Publication date
GB2500357B (en) 2017-09-06
CR20130298A (es) 2013-07-09
GB2500357A (en) 2013-09-18
AR084435A1 (es) 2013-05-15
DOP2013000144A (es) 2013-10-15
MX2010014484A (es) 2012-06-21
WO2012085785A1 (es) 2012-06-28
RU2608928C2 (ru) 2017-01-26
ES2422877R1 (es) 2013-09-26
CA2822213C (en) 2018-06-19
CO6751242A2 (es) 2013-09-16
RU2013127794A (ru) 2015-01-27
CL2013001731A1 (es) 2014-01-10
US20130316005A1 (en) 2013-11-28
GB201312583D0 (en) 2013-08-28
ES2422877A2 (es) 2013-09-16
BR112013015489A2 (pt) 2018-05-15
CA2822213A1 (en) 2012-06-28
PE20140697A1 (es) 2014-06-25
ES2422877B1 (es) 2014-07-17
GT201300169A (es) 2014-04-04
US9433602B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PH12017501306A1 (en) Inhibitors of histone demethylases
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
IN2012DN02805A (es)
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
MX350046B (es) Tratamientos para trastornos gastrointestinales.
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
EA201171414A1 (ru) Ингибиторы белков семейства iap
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
MY161769A (en) Pharmaceutical composition for treating hcv infections
CL2008003711A1 (es) Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica.

Legal Events

Date Code Title Description
FG Grant or registration